Cingulate Q3 10-Q: $23.2M Cash, $7.7M Quarterly Loss, Going Concern Restated
CING sits 34% above its 52-week low of $3.16.
Summary
Cingulate's Q3 10-Q shows $23.2 million of cash, a $7.7 million quarterly net loss and a restated going-concern warning, with the runway into mid-2027 dependent on continued ATM and equity-line sales.
Key Events · Earnings and Guidance · CING
-
Q3 Loss and Cash Position
Net loss was $7.7 million for the quarter and $22.9 million for the nine months; cash and cash equivalents stood at $23.2 million at September 30, 2026 versus $11.0 million at December 31, 2025.
-
Going Concern Doubt Restated
Management states substantial doubt about the Company's ability to continue as a going concern within one year after the financial statements are issued, with an accumulated deficit of $155.3 million.
-
Cash Burn Versus Financing
Operating activities used $20.2 million in the first nine months while financing activities provided $32.6 million, including $34.3 million of net stock and warrant proceeds.
-
SG&A Doubles on Launch Prep
SG&A rose 116.5% to $14.2 million for the nine months, including $7.2 million of pre-commercialization costs, while R&D fell 15.3% to $6.6 million.
Analysis · CING · Life Sciences
The 10-Q puts hard numbers behind the same-day earnings 8-K and repeats the going-concern warning that has hung over Cingulate since its last quarterly report. Cash of $23.2 million at September 30 is up from $11.0 million at year-end 2025, but that came from $34.3 million of net financing proceeds against $20.2 million of operating cash burn, and management still says substantial doubt exists about continuing as a going concern within a year of issuance. The spending mix has shifted toward launch preparation: SG&A more than doubled to $14.2 million for the nine months, including $7.2 million of pre-commercialization costs, while R&D fell 15.3% to $6.6 million. The company's own runway statement extends into mid-2027, which overlaps the targeted December 2026-January 2027 CTx-1301 NDA resubmission, so the financing treadmill has to keep turning until the FDA acts.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CING was trading at $4.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $62.5M. The 52-week trading range was $3.16 to $11.89. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.